Profusa, Inc. (Nasdaq: PFSA) said its shareholders approved all proposals at the company's 2026 Annual Meeting of Shareholders held June 23, 2026, in Berkeley, California.

The approved measures include authorization for the company's planned acquisition of the PanOmics multi-omics diagnostics platform from BioInsights LLC, approval of debt conversion matters aimed at strengthening the balance sheet, and authorization for a reverse stock split if the board determines it necessary to maintain Nasdaq listing compliance.

Shareholders also approved the election of a director, an amendment to the company's equity incentive plan, and authority to adjourn the meeting if additional shareholder solicitation was needed.

"We are grateful that our shareholders responded with their support," said Ben Hwang, Ph.D., CEO and Chairman of Profusa. "Today's outcome reflects a strong endorsement of the Company's strategic direction and provides management with important flexibility to execute on initiatives designed to strengthen the Company, advance innovation and create long-term shareholder value."

With shareholder approval secured, Profusa said it intends to focus on completing the PanOmics transaction, maintaining Nasdaq listing compliance, and advancing commercialization initiatives. Detailed voting results were filed in a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on June 23, 2026.